

February 3, 2022



## **Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference**

HARRISON, N.Y., Feb. 3, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today that the company will present at the Guggenheim Healthcare Talks, 2022 Oncology Conference, taking place virtually February 9-February 11, 2022.

Dr. Barry Kappel, CEO and President of Sapience, will present a company overview on Friday February 11<sup>th</sup>, at 11:30 am ET. Sapience management will also participate in one-on-one meetings with investors during the conference.

### ***About Sapience Therapeutics***

Sapience Therapeutics, Inc. is a privately held, clinical stage biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide therapeutics that disrupt protein-protein interactions, Sapience's molecules hold potential to target intracellular interactions that are traditionally considered "undruggable targets". Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. For more information on Sapience Therapeutics, please visit [www.sapiencetherapeutics.com](http://www.sapiencetherapeutics.com) and engage with us on [LinkedIn](#).

### ***Cautionary Note on Forward-Looking Statements***

This press release contains forward-looking statements. Any statements herein other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience's preclinical and clinical development programs). These forward-looking statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience's product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. Forward-looking statements speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise, except as required by law.

### **Contacts**

Sapience Therapeutics, Inc.:

Barry Kappel, Ph.D., M.B.A.  
President and Chief Executive Officer  
[info@sapiencetherapeutics.com](mailto:info@sapiencetherapeutics.com)

**Media and Investor Contact:**

Amy Conrad  
Juniper Point  
(858) 366-3243  
[amy@juniper-point.com](mailto:amy@juniper-point.com)

SOURCE Sapience Therapeutics